Recently, Professor Lin Yang and Dr. Wen Wang from the College of Animal Science at South China Agricultural University, in collaboration with Researcher Xue Wang from Shandong University, unveiled a new potential for Lactobacillus rhamnosus (LGG) as a therapeutic strain, offering a novel approach to alleviate gout and Hyperuricemia (HUA) and its complications in geese. The findings have been published online in npj Biofilms and Microbiomes.
Lactobacillus rhamnosus GG (LGG) mitigates hyperuricemia through the intestinal-liver-kidney axis. Figure provided by the respondent.
Hyperuricemia is a metabolic disorder caused by purine metabolism abnormalities, which, when accompanied by joint urate deposition and uric acid nephrolithiasis, progresses to gout. Gout, as a type of human metabolic disease, is also a significant challenge in goose farming production. Geese are highly sensitive to gout, with high incidence and mortality rates. Approximately 400-500 million geese are consumed in China every year, with 30-50% of them suffering from gout during the growth period.
Previous studies on gout have primarily used mice as models. The team led by Wen Wang established a new hyperuricemia research model in geese and found a significant correlation between changes in the abundance of intestinal lactobacilli and desulfurizing bacteria and hyperuricemia. They further elucidated the role of LGG in absorbing and degrading nucleosides, reducing intestinal and renal uric acid reabsorption, and downregulating hepatic uric acid synthesis. This reveals the mechanism by which LGG alleviates purine metabolism disorders through the "intestinal-liver-kidney axis," providing a potential probiotic therapy for gout nutrition regulation in geese.
The above research was supported by the National Excellent Youth Foundation Project, the Guangdong Provincial Outstanding Youth Foundation Project, the National Waterfowl Industry Technology System, and other projects.
Related paper information: https://doi.org/10.1038/s41522-024-00486-9
